Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.75 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.75 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.59 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.57 |
| ▸ | F10 | P00742 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9701193 | 0.99 | TAS1R3 (0.73) | TAS1R3TAS1R2TAS1R1SSTR3F10 | |
| Hydrochloric Acid SCHEMBL9699958 | 0.99 | TAS1R3 (0.73) | TAS1R3TAS1R2TAS1R1SSTR3F10 | |
| SCHEMBL700604 | 0.86 | TAS1R3 (1.00) | TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL11454876 | 0.84 | TAS1R3 (0.68) | TAS1R3TAS1R2TAS1R1SSTR3F10 | |
| SCHEMBL9699898 | 0.83 | TAS1R3 (0.71) | TAS1R3TAS1R2TAS1R1SSTR3F10 | |
| SCHEMBL3366745 | 0.83 | TAS1R3 (0.71) | TAS1R3TAS1R2TAS1R1SSTR3F10 | |
| SCHEMBL10340087 | 0.82 | TAS1R3 (0.70) | TAS1R3TAS1R2TAS1R1SSTR3F10 | |
| SCHEMBL10340088 | 0.82 | TAS1R3 (0.70) | TAS1R3TAS1R2TAS1R1SSTR3F10 | |
| SCHEMBL11457335 | 0.82 | TAS1R3 (0.70) | TAS1R3TAS1R2TAS1R1SSTR3F10 | |
| Hydrochloric Acid SCHEMBL9700027 | 0.82 | TAS1R3 (0.69) | TAS1R3TAS1R2TAS1R1SSTR3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | TAS1R3 1195/4885TAS1R2 1660/4885TAS1R1 1292/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | TAS1R3 3512/4885TAS1R2 4158/4885TAS1R1 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.